TrialNeoplasia (New York, N.Y.)2010

Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

Petronella O Witteveen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.